Align Technology, Inc.
ALGNHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeAlign Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The $11.27B market capitalization puts ALGN squarely in large-cap range for its industry. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth.
Market Cap
$11.27B
Beta
1.64
P/E (TTM)
27.59
P/E (Fwd)
12.64
EPS (TTM)
$5.75
EPS (Fwd)
$12.55
ROE
10.2%
ROA
7.4%
Cash
$1.10B
Total Debt
$120.8M
Free CF
$584.4M
52W Change
16.8%
Annual Financials
Cash vs Debt
Where ALGN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ALGN finished 11.15% below its 150-day moving average ($174.41) and 8.95% below its 200-day moving average ($170.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALGN overbought or oversold?
At the September 2, 2026 close, ALGN's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.10B in cash and $120.8M in debt, ALGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $584.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 10.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $3.73B (2022) to $4.03B (2025).
A beta of 1.64 means ALGN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, ALGN has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing ALGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.